Middle East and Africa Tissue Diagnostics Market Research Report - Segmented By Product Type, Application, End User, Disease & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Trends & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 4095
Pages: 130

MEA Tissue Diagnostics Market Size (2022 to 2027)

The Middle East and Africa Tissue diagnostics Market size is predicted to be USD 234.08 million in 2022. It is further estimated to be growing at a CAGR of 6.4% and value USD 319.21 million by 2027.

Due to the rising cancer incidence and prevalence, increased use of cancer diagnosis, and enhanced cancer detection healthcare infrastructure, the Middle East and Africa tissue diagnostics market is booming. A rising number of industry actors are attempting to improve advanced tissue-diagnostics-based companion tests, which is good for business. An increase in cancer incidence rates and the increased usage of automated tissue diagnostics to diagnose diseases are projected to drive the Middle East and Africa tissue diagnostics market.

As the incidence of cancer, healthcare costs, and spending on cancer research and drug development all rise, the Middle East and Africa tissue diagnostics market is predicted to expand. Furthermore, increased lifestyle changes, rising food and tobacco use, and increased alcohol and common lifestyle disorders are expected to boost market demand in the Middle East and Africa. In addition, the growing number of government programs to raise awareness about the importance of early cancer detection is expected to propel the tissue diagnostics market forward. The Middle East and Africa tissue diagnostics markets are also likely to rise in response to the world's aging population.

Additionally, factors such as increased investments in new technology research and development, the emergence of efficient and accurate products, growing demand for personalized medicines, and untapped market potential due to a lack of efficient diagnostics tests for non-small lung cancer detection are expected to provide lucrative opportunities for tissue diagnostics market growth in this region. Furthermore, demand for tissue diagnostics is likely to increase as healthcare institutions grow in size.

Stringent regulations for the approval of new products and instruments that are highly expensive, lack of access to healthcare indicators in underdeveloped countries, and social stigma associated with cancer are all factors that limit the growth of the Middle East and Africa tissue diagnostics market. Furthermore, rural communities are less aware of new medical innovations, which modestly impacts the Middle East and Africa market demand.

On March 19, 2020, the World Health Organization (WHO) proclaimed a pandemic crisis. Due to the shutdown of production facilities, a scarcity of raw materials, and a lack of workforce, the healthcare market's research and development show a sharp drop in sales during the lockdown. Tissue diagnostics are explicitly employed in cancer patients. Acute coronavirus infection is very common in cancer patients. Therefore, diagnostic labs have been significantly impacted, particularly those examining cell and tissue samples.

This research report on the Middle East and Africa tissue diagnostics market has been segmented and sub-segmented into the following categories:

By Product Type: 

  • Instruments
  • Consumables

By Application: 

  • Immunohistochemistry
  • Hematoxylin and Eosin
  • In Situ Hybridization

By End User: 

  • Contract Research Organizations
  • Hospitals
  • Diagnostic Laboratories
  • Research Organizations
  • Biotechnology Companies

By Disease: 

  • Lung Cancer
  • Lymphoma
  • Pancreatic Cancer
  • Breast Cancer
  • Others

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The Middle East and Africa market is predicted to grow at a moderate growth rate throughout the forecast period due to increased attention from government and private sectors in developing countries such as Saudi Arabia, the United Arab Emirates, Israel, and the rest of MEA. In addition, as a result of people's unhealthy lifestyles, cancer incidence is increasing each year, boosting the market for tissue-based diagnosis.

For example, Saudi Arabia, the United Arab Emirates, and Israel are fast-growing economies in the Middle East and Africa. The region's market growth is due to the growing healthcare sector and active key market players. In addition, personalized medicine has expanded dramatically as sequencing technologies and healthcare IT systems have become more widely used in clinical workflows, which is expected to drive the Tissue Diagnostics market in the area.

The tissue diagnostics market in Saudi Arabia is predicted to grow significantly over the forecast period. Saudi Arabia's market expansion is encouraged by the factors such as increased healthcare spending, expanding cancer diagnostic facilities, and government support.

Israel is expected to lead the Middle East and Africa Tissue Diagnostics market. The country's market growth is influenced by the availability of healthcare infrastructure, accessibility to healthcare facilities, and advancements in healthcare technology.


Companies that have a presence in the MEA Tissue diagnostics Market profiled in this report are F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, Abbott Laboratories, Agilent Technologies, BioGenex, Danaher Corporation, Cell Signaling Technology, and Ventana Medical Systems.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample